Literature DB >> 12371981

Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?

Peter Stenvinkel1, Christoph Wanner, Thomas Metzger, Olof Heimbürger, Francesca Mallamaci, Giovanni Tripepi, Lorenzo Malatino, Carmine Zoccali.   

Abstract

BACKGROUND: Elevated C-reactive protein (CRP) is a strong predictor of cardiovascular events and all-cause mortality in end-stage renal disease (ESRD) patients. However, although sex hormones may influence serum levels of inflammatory proteins, gender has not been taken into consideration in previous studies of inflammation and outcome in ESRD patients.
METHODS: We included 663 (374 males) ESRD patients (59 +/- 1 year) from three European renal centers (Sweden, Germany and Italy) in which CRP levels and outcome data (follow-up 33 +/- 1 months) were available. The relation between outcome and serum levels of the soluble intercellular adhesion molecule (sICAM-1) was evaluated in 312 of the patients.
RESULTS: The present study shows that elevated CRP is a strong predictor of outcome, but whereas no difference in all-cause mortality was observed between non-inflamed (CRP <or=3.4 mg/L) males and females, inflamed males had a significantly (log rank 6.1; P = 0.01) higher mortality rate than inflamed females. A strong positive correlation between CRP and sICAM-1 was found in the combined patient material (rho = 0.37; P < 0.0001) as well as in the male (rho = 0.25; P < 0.01) and female (rho = 0.52; P < 0.0001) subgroups. The Cox proportional hazard model showed that whereas both elevated sICAM-1 and log CRP predicted outcome in males, neither predicted outcome significantly in females.
CONCLUSIONS: As inflamed female patients have a better outcome that inflamed males the present observation suggests that sex hormones may have important cardioprotective effects that limit the effect of inflammation on vascular injury in female ESRD patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12371981     DOI: 10.1046/j.1523-1755.2002.00637.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  37 in total

Review 1.  Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.

Authors:  Alberto Ortiz; Ziad A Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

2.  Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.

Authors:  Liesbeth Viaene; Björn K I Meijers; Bert Bammens; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

3.  Clinical predictors of decline in nutritional parameters over time in ESRD.

Authors:  Claire H den Hoedt; Michiel L Bots; Muriel P C Grooteman; Neelke C van der Weerd; E Lars Penne; Albert H A Mazairac; Renée Levesque; Peter J Blankestijn; Menso J Nubé; Piet M ter Wee; Marinus A van den Dorpel
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

4.  Inflammation and the bone-vascular axis in end-stage renal disease.

Authors:  L Viaene; G J Behets; S Heye; K Claes; D Monbaliu; J Pirenne; P C D'Haese; P Evenepoel
Journal:  Osteoporos Int       Date:  2015-08-21       Impact factor: 4.507

Review 5.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed.

Authors:  Christiaan L Meuwese; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2011-03       Impact factor: 28.314

6.  IL-1β receptor antagonist reduces inflammation in hemodialysis patients.

Authors:  Adriana M Hung; Charles D Ellis; Ayumi Shintani; Cindy Booker; T Alp Ikizler
Journal:  J Am Soc Nephrol       Date:  2011-02-10       Impact factor: 10.121

Review 7.  Cardiovascular risk in the peritoneal dialysis patient.

Authors:  Raymond T Krediet; Olga Balafa
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

8.  Soluble Tumor Necrosis Factor Like Weak Inducer of Apoptosis and Vitamin D in Hemodialysis Patients: Relation to Carotid Intima-Media Thickness.

Authors:  Farahnaz Askarian; Amir Ghorbanihaghjo; Hassan Argani; Davoud Sanajou; Nima Nasehi; Roya Askarian; Ravan Ahmadi; Nadereh Rahtchizadeh
Journal:  Indian J Clin Biochem       Date:  2017-07-22

9.  CCR5 deletion protects against inflammation-associated mortality in dialysis patients.

Authors:  Friso L H Muntinghe; Marion Verduijn; Mike W Zuurman; Diana C Grootendorst; Juan Jesus Carrero; Abdul Rashid Qureshi; Karin Luttropp; Louise Nordfors; Bengt Lindholm; Vincent Brandenburg; Martin Schalling; Peter Stenvinkel; Elisabeth W Boeschoten; Raymond T Krediet; Gerjan Navis; Friedo W Dekker
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

10.  Can Serum Gdf-15 be Associated with Functional Iron Deficiency in Hemodialysis Patients?

Authors:  Hakki Yilmaz; Muzaffer Cakmak; Tahir Darcin; Osman Inan; Mukadder Ayse Bilgic; Nuket Bavbek; Ali Akcay
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-27       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.